Ezetimibe/simvastatin

Drug Profile

Ezetimibe/simvastatin

Alternative Names: Inegy; MK-0653A; Simvastatin/ezetimibe; Vytorin; Zetia™/Zocor®; Zintrepid; Zocor®/Zetia™

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck/Schering-Plough Pharmaceuticals
  • Class Antihyperlipidaemics; Azetidines; Naphthalenes; Small molecules
  • Mechanism of Action Cholesterol absorption inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute coronary syndromes; Hypercholesterolaemia; Hyperlipidaemia
  • Discontinued Aortic valve stenosis

Most Recent Events

  • 27 Apr 2017 Generic equivalent available in USA for Hypercholesterolaemia
  • 28 Feb 2017 Merck has patent protection for ezetimibe/simvastatin (Vytorin®) in Europe and Japan (Merck Annual report 2016)
  • 15 Feb 2016 Merck receives complete response letter from the FDA for ezetimibe/simvastatin in Acute coronary syndromes
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top